Treatment of generalized infantile myofibromatosis with sorafenib and imatinib: A case report

Behzad Bidadi, Andrea Watson, Brenda Weigel, Andre Oliveira, Justin Kirkham, Carola Arndt

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Infantile myofibromatosis (IM) is characterized by solitary musculoskeletal nodules presenting during infancy but can manifest as multiple lesions with visceral involvement. Multicentric IM with visceral involvement carries a high risk of mortality and there is no consensus on treatment. We present a case of a patient with multicentric IM and pulmonary involvement who progressed on several chemotherapeutic regimens and subsequently had a complete response to sorafenib and later imatinib. This report describes the novel use of sorafenib and imatinib to treat generalized IM and the role of continued tyrosine kinase inhibitor therapy to maintain remission.

Original languageEnglish (US)
Article numbere28288
JournalPediatric Blood and Cancer
Volume67
Issue number6
DOIs
StatePublished - Jun 1 2020

Keywords

  • imatinib
  • infantile myofibromatosis
  • soft tissue tumor
  • sorafenib
  • targeted therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Treatment of generalized infantile myofibromatosis with sorafenib and imatinib: A case report'. Together they form a unique fingerprint.

  • Cite this